| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1995;92:2299-2305.)
© 1995 American Heart Association, Inc.
Articles |
From the Montreal Heart Institute (A.M., J.Y.T.L., D.H., D.R.), Montreal, Canada; Cardiac Catheterization Laboratory (A.V.K.), Palo Alto Veterans Administration Hospital, Palo Alto, Calif; Division of Cardiovascular Medicine (P.G.Y., A.V.K.), Stanford University School of Medicine, Stanford, Calif; LocalMed, Inc (J.R.K., G.W.G., E.J.K., J.B.S., A.V.K.), Palo Alto, Calif; and the Department of Medicine (J.B.S.), Sequoia Hospital, Redwood City, Calif.
Correspondence to Aaron V. Kaplan, MD, 1820 Embarcadero Rd, Palo Alto, CA 94303.
| Abstract |
|---|
|
|
|---|
Methods and Results The delivery of horseradish peroxidase via
the infusion sleeve was studied in a porcine explanted heart model.
Under physiological conditions, arteries underwent
balloon injury (
10% overstretch), after which horseradish
peroxidase (2.5 mL) was delivered at specific pressures.
Cross-sectional analysis demonstrated greater staining when
the agent was delivered at increasing pressures. The infusion sleeve
was evaluated in an in vivo canine coronary model. With an
infusion sleeve loaded over a standard dilatation catheter through a 9F
guide, overstretch balloon injury was performed, after which
fluoresceinated heparin was delivered. Animals were killed
2 hours after delivery. Fluoresceinated
heparintreated segments demonstrated high fluorescence
signals, localizing with smooth muscle cell nuclei with less activity
in the interstitium. The functional significance of intramural heparin
delivery was studied in a porcine carotid model. In the presence of
111In-labeled platelets, arteries underwent
overstretch injury followed by delivery of heparin (50 or 100 units/kg)
or vehicle. Platelet deposition was reduced at 30 minutes (57%,
P<.01) and 12 hours (39%, P=.06) compared with
saline controls.
Conclusions Agent delivery via the infusion sleeve is pressure dependent; transmural delivery is possible with minimal disruption of arterial wall architecture; the infusion sleeve is compatible with standard angioplasty equipment; and heparin delivery at the site of balloon injury significantly reduces platelet deposition in a porcine model for a minimum of 12 hours.
Key Words: angioplasty restenosis drug delivery system
| Introduction |
|---|
|
|
|---|
A successful local delivery system must deliver sufficient agent to the site of interest with an acceptable safety profile without inducing injury that might lead to restenosis. Furthermore, the delivery system must be easy to use and cost effective.
First-generation drug-delivery systems have been hampered by ineffective delivery and/or unacceptable injury.4 The structure of the first-generation drug-delivery systems consists primarily of modified angioplasty balloon catheters. The simplest of the modified PTCA balloon systems is the perforated balloon, first described by Wolinsky and Thung.4 The conditions under which an agent exits the balloon are determined by proximal inflation pressure, perforation size and number, and the fit of balloon artery. Acceptance of the perforated balloons has been hindered by the "jet" injury associated with the use of these catheters.5 The injury associated with the perforated balloon system may be due in part to the inability to precisely control the delivery conditions. With a perforated balloon catheter, both the balloon artery fit and drug-delivery conditions are determined by inflation pressure. For example, if 8 atm is required to ensure optimal fit, drug delivery must also be performed at 8 atm, even if delivery at this pressure inflicts unacceptable arterial damage.5 To overcome these limitations, balloon systems with porous membranes have been developed.6 The outer porous membrane limits the flow of the agent out of the balloon, reducing it to a low-pressure "weeping" balloon delivery method. It is uncertain whether low-pressure delivery can supply sufficient agent deep into the vessel wall.
To resolve these problems, the parameters associated with agent transfer to the arterial wall require further definition. Delivery of an agent in an aqueous vehicle requires two distinct steps: the apposition of drug-delivery elements against the arterial wall and the delivery of the agent into the wall. To better define the parameters associated with local delivery, we designed a catheter system that allows independent control of both apposition and drug delivery.
| Methods |
|---|
|
|
|---|
|
|
When used in vivo, the infusion sleeve is loaded onto a standard balloon dilatation catheter of the operator's choice. PTCA is performed in the usual fashion, with the infusion sleeve retracted within the guide (retracted configuration). After angioplasty, the infusion sleeve is advanced over the dilatation catheter, aligning the infusion region of the infusion sleeve with the underlying PTCA balloon (aligned configuration). Drug delivery is then performed under specific apposition and infusion conditions. After drug delivery, the infusion sleeve can be retracted, allowing the unsheathed PTCA balloon to perform additional angioplasty; alternatively, the infusion sleeve/PTCA balloon catheter assembly can simply be removed.
For selected parts of the study, the infusion sleeve was specially manipulated to inactivate three lumens, leaving one active lumen. This was done to have actively treated and control sectors within each arterial segment. In the explanted heart model studies, infusion sleeves with either one or four active lumens were used as indicated. Infusion sleeves with one active lumen were used in the canine studies. Due to the larger diameter of the porcine carotid arteries (compared with porcine or canine coronary arteries), infusion sleeves with six lumens (all active) were used. All studies were performed in accordance with institutional guidelines.
Computer-Controlled Pump System
A computer-controlled pump
system was used to ensure precise
delivery and for monitoring pressure during delivery. The agent was
loaded into a syringe mounted in a Harvard Apparatus pump,
and connected to the proximal end of the infusion sleeve. Proximal
pressure was monitored with a Wheatstone Bridge pressure transducer
(XTC-190-200, Kulite Semiconductor Products).
Explanted Porcine Heart Model
Freshly harvested porcine
hearts were obtained from a
slaughterhouse and transported to our facility in iced
physiological saline solution. The left
coronary ostium was isolated, after which a standard 9F short
side arm sheath was introduced subselectively into the left anterior
descending coronary artery. The artery was perfused with
physiological saline at 37°C at systemic
pressures for a minimum of 5 minutes. Arterial segments (3
mm diameter) were identified by intravascular ultrasound with
standard techniques (CVIS, Inc). The infusion sleeve was loaded onto a
standard PTCA balloon catheter (3.0 mm). With the infusion sleeve in
the retracted configuration, overstretch injury was performed by
inflating the balloon to its nominal pressure for 60 seconds. After
balloon deflation, the infusion sleeve was advanced over the PTCA
catheter to the aligned configuration. The balloon was then reinflated
to the same pressure, and the marker agent (HRP, 1.0 mg/mL; Sigma
Chemical Co) was delivered at a specified proximal pressure.
The artery was then perfused with physiological saline for 5 minutes and fixed with isotonic glutaraldehyde. Frozen sections were prepared by a standard technique. HRP was detected with 3',3-diaminobenzidineH2O2 reaction.7 Arterial cross sections were evaluated by technicians blinded to the specific drug-delivery protocol used. Each arterial section was divided visually into 18 sectors. The presence of discoloration was noted in each sector with the use of a binary scale. The results are presented as the percentage of sectors with HRP discoloration present ±SEM. Injury to the arterial wall was graded in a similar fashion. The two-sided paired Student's t test was used when comparing drug-delivery groups.
Injury associated with drug delivery was evaluated by delivering physiological saline. Arteries were fixed in formaldehyde and stained with hematoxylin and eosin by a standard technique.
Acute Canine Coronary Model
Under general anesthesia, a
cutdown was performed on
the right carotid artery. A 9F short side arm sheath was placed and a
standard 9F hockey stick guide catheter was introduced into the
ascending aorta to the ostium of the left main coronary artery.
Intracoronary nitroglycerin (100 µg) was
delivered, after which coronary arteriography was performed.
The internal diameter of the arterial lumen was determined
by intravascular ultrasound with a standard technique.
An infusion
sleeve was then loaded onto an appropriate-size PTCA
balloon catheter. With the infusion sleeve in the retracted
configuration, angioplasty injury was performed at
110% stretch for
60 seconds. With the PTCA balloon deflated, the infusion sleeve was
tracked over the PTCA catheter to the aligned configuration. The
balloon was then reinflated to 4 atm, and 2.5 mL of FITC-heparin
(Polysciences, Inc) (150 units/mL) was delivered over approximately 20
seconds with an estimated proximal pressure of 100 psi.
The animal was maintained under general anesthesia for approximately 2 hours after delivery, when it was killed. Frozen arterial sections were prepared with a standard technique and evaluated with fluorescence microscopy.
Porcine Carotid Overstretch Model
The functional significance
of heparin delivery was evaluated in
a well-described model of platelet thrombus formation at the
site of angioplasty injury.8 9 Cross-breed Yorkshire
swine received autologous 111In-labeled platelets
that were allowed to circulate for a minimum of 12 hours. With the
animal under general anesthesia, femoral
arterial access was established, after which a bolus of
heparin (50 units/kg) was administered via the arterial
sheath. Carotid artery overstretch was performed with a standard
balloon dilatation catheter (8.0 mm x 2.0 cm, Meditech, Inc). Five
inflations of 30 seconds at 6 atm each were performed at 1-minute
intervals. Drug delivery was then performed on the index artery. A
six-lumen infusion sleeve was loaded onto a standard balloon
dilatation catheter (6.0 mmx2.0 cm, Meditech, Inc) and placed at the
site of previous arterial injury. Heparin was delivered (8
mL, 50 units/kg) with a balloon support pressure of 2 atm at a proximal
pressure of approximately 200 psi. Saline (8 mL) was then delivered to
the contralateral carotid artery at the site of previous overstretch
injury after a similar protocol. Animals were killed at 30 minutes or
12 hours after the angioplasty procedure. For animals killed at 12
hours, 100 units/kg heparin was infused locally. The carotid
arterial segments were then fixed in situ with antegrade
perfusion of glutaraldehyde and harvested, and the
radioactivity associated with labeled platelets deposited at the
site of balloon injury was measured with a gamma counter. The extent of
platelet deposition at the site of angioplasty injury was
calculated as previously described.8 9
| Results |
|---|
|
|
|---|
|
|
|
Qualitative
review of arterial sections treated at proximal
pressures of 150 and 200 psi demonstrated frequent areas of medial
separation that were not found in the control areas. In sections
treated at proximal pressures of 50 and 100 psi, areas of medial
separation were rarely observed. Hematoxylin and eosin slides from
representative arterial sections treated
with saline (8 mL, proximal pressure of 100 psi, balloon support
pressure of 6 atm) via an infusion sleeve with four active lumens and
control sections are shown in Fig 5
. The treated
segments demonstrated subtle changes in the nuclear architecture with
karyorrhexis and pyknosis. No significant differences were noted in
terms of medial tears or dissections.
|
Acute Canine Coronary Model
The ability to deliver an agent
in vivo with the infusion sleeve
was evaluated in an acute canine coronary model. The infusion
sleeve was loaded onto a 3.0-mm standard PTCA balloon catheter and
introduced into a standard 9F guide catheter. With the infusion sleeve
in the retracted configuration, overstretch arterial injury
of the midportion of the left anterior descending coronary
artery was performed. After balloon deflation, the infusion sleeve was
tracked over the balloon while maintaining the position of the PTCA
balloon. The balloon was reinflated, and the agent (FITC-heparin) was
delivered (proximal pressure of 100 psi). The animal was killed 2 hours
after local drug delivery. Gross examination revealed no abnormalities.
Fluorescence microscopy revealed transmural deposition of
heparin over an arc of approximately 120° in the maximal stained
section. Intense fluorescence was noted to localize with the
smooth muscle cell nuclei. Less intense fluorescence was noted
within the interstitial spaces (Fig 6
).
|
Porcine Carotid Overstretch Model
The functional significance
of heparin delivery into the
angioplasty-injured arterial segment was then evaluated
in the porcine overstretch injury model. At 30 minutes, there was a
57% reduction in platelet deposition at the sites of deep
arterial injury compared with control segments (10.7±2.7
versus 24.8±6.5x106
platelets/cm2, n=10, P<.01). This
reduction in platelet deposition persisted for 12 hours when a 39%
reduction in platelet deposition compared with control segments
(19.1±6.6 versus 31.4±13.6x106
platelets/cm2, n=10, P=.06) was
observed (Fig 7
).
|
| Discussion |
|---|
|
|
|---|
Before these issues are addressed, the ability of the system to deliver the marker agent must be evaluated. Data from the explanted heart model studies demonstrate the ability of the infusion sleeve to decouple apposition (balloon inflation) from drug infusion (proximal pressure). This feature was used to identify a protocol capable of transmural delivery of the agent with minimal changes within the medial architecture. Histological evaluation of the arteries from the explanted heart studies demonstrated subtle injury when the agent was delivered with a proximal pressure of 100 psi. It seems unlikely that injury of this nature would have an impact on the structural integrity of the artery leading to luminal compromise or perforation.
It is possible that delivery of an agent might add to the injury associated with lesion dilation leading to an increased restenosis rate. Santoian and colleagues5 reported "jet" injury associated with high-pressure delivery in connection with the Wolinsky balloon catheter. The impact of the type of injury induced by the Wolinsky balloon on restenosis is unclear.5 7 In contrast to the perforated balloon systems, the histological injury associated with delivery via the infusion sleeve seems minimal. Further studies are ongoing to evaluate the effect of the injury (if any) on myointimal hyperplasia in appropriate animal models.
The acute canine studies demonstrated the ability of the infusion sleeve to deliver a biologically appropriate agent in a setting closely resembling the clinical situation. Two hours after delivery the agent is detectable. The observation of nuclear localization suggests that the FITC-heparin is qualitatively similar to what has been observed in similar models with a passive delivery device.10 Furthermore, the ability to perform overstretch injury and drug delivery in vivo in the canine coronary circulation with the infusion sleeve in conjunction with a 9F guide demonstrates the feasibility of this approach.
Radiolabeled platelet studies in the porcine carotid overstretch model were designed to demonstrate the functional utility of heparin when delivered with a clinically relevant protocol. An important feature of this protocol is that both heparin and saline control deliveries were performed in each animal. The effect of heparin entering the systemic circulation as a result of local delivery was evaluated by comparing platelet deposition in the heparin-treated segments with that in the contralateral control segments. Local delivery of heparin resulted in a significant reduction in platelet deposition and was observed at both 30 minutes and 12 hours. It is important to note that the dosing regimen with a total of 100 to 150 units/kg heparin is clinically feasible. Recent studies have demonstrated the clinical utility of agents that have been shown to reduce platelet thrombus formation at the site of balloon injury in a similar model.11 When a GP IIb/IIIa inhibitor, 7E3, was administered systemically to patients at high risk for abrupt closure after angioplasty, a 35% reduction in ischemic events during the initial 30-day period was observed, although there was an increased risk of bleeding. This clinical benefit regarding ischemic events was sustained for at least 6 months, implying a reduction in clinical restenosis.12 These results provide indirect evidence that reduction of platelet deposition at the site of PTCA-induced arterial injury may result in a reduction in both abrupt closure and restenosis. Further studies are under way to characterize the effects of locally delivered heparin and other antithrombotics and to document whether the same benefits may be observed with less significant risks of bleeding when these agents are delivered locally.
The concept of catheter-based local drug delivery was first demonstrated by Wolinsky and Thung4 with a perforated balloon catheter. The acceptance of this catheter has been hindered by the injury associated with this type of local delivery. Other groups have sought to limit the injury associated with this delivery by limiting the energy of the agent as it exits the catheter. The Dispatch Catheter (Boston Scientific) has a novel design that permits prolonged bathing of the arterial wall with the agent. This system is an over-the-wire nondilatory system with a helical balloon that forms a spiral around a urethane sheath. Inflation brings the helical balloon against the arterial wall while expansion of the central sheath permits simultaneous distal perfusion. The agent is infused via the spaces between the coils. Heparin delivery via the Dispatch Catheter has been studied in a porcine coronary angioplasty model that is used to measure radiolabeled platelet deposition. At 1 hour, no reduction in platelet deposition was observed compared with control segments. Another low-pressure delivery system is the Microporous Infusion Catheter, which is under development by Cordis Corporation. This is a perforated balloon covered by a porous membrane. When the system is pressurized the balloon is inflated, and the agent "weeps" from the outer membrane. With this catheter in an in vivo porcine coronary model, HRP has been delivered into the media after overstretch injury. The delivery pattern is circumferential within the media.6 Other balloon-based systems have been designed to allow careful titration of drug-delivery conditions. These systems include the Transport Catheter (Cardiovascular Dynamics/Boston Scientific) and Channel Balloon Catheter (Boston Scientific). These systems have been recently reviewed.13
When comparing different drug-delivery catheter systems, the
relation between proximal pressure and distal drug-delivery
conditions, ie, the hydraulic head of the agent exiting the catheter,
may not be equal in different systems. The distal delivery conditions
may be quite different when an agent is delivered with a proximal
pressure of 100 psi in the infusion sleeve compared with the delivery
of the same agent at 100 psi via another catheter with different
characteristics. In a closed hydraulic system, such as a standard PTCA
balloon catheter, the proximal inflation pressure when stabilized will
be equal to the distal pressure in the balloon. In an open hydraulic
system in which there is fluid flow, there can be a substantial
pressure drop along the catheter. The pressure drop between the
proximal and distal ends is a function of many factors, including fluid
viscosity, catheter length, cross-sectional area, and geometry of
the drug-delivery conduit. In the infusion sleeve, there is a
gradual pressure drop of approximately 90% between the proximal and
distal ends. This has been verified with specially instrumented
catheters to allow measurement of distal tip pressure during agent
infusion. These studies demonstrated a pressure drop to approximately
one-tenth of proximal infusion pressure. It is important to note
that there is no significant change in hydrodynamics between the
proximal and distal ends of the perfusion array. In the protocol used
to deliver the agent in the acute canine studies, the distal pressure
was
10 psi (data not shown). When comparing the infusion sleeve with
other delivery systems, it is important not to assume that equal
proximal pressures will result in equal distal drug-delivery
conditions.
Study Limitations
The studies performed in the explanted
heart model or in vivo in
the coronary or carotid artery were designed to evaluate drug
delivery under different conditions. The drug was delivered adequately
with this catheter system in these models. It is important to note,
however, that all of the models described involved normal, nondiseased
arteries. This substrate for drug delivery may be different for the
human atherosclerotic arterial segment after
angioplasty.
Conclusions
The results of the present study demonstrate that
drug
delivery via the infusion sleeve is pressure dependent and feasible
with the use of standard PTCA equipment within a 9F guide. Transmural
delivery is possible with minimal disruption of arterial
wall architecture. Heparin delivery at the site of balloon injury
significantly reduces platelet deposition in a porcine model for a
minimum of 12 hours.
Local delivery of heparin with the infusion sleeve is a practical and promising approach for the prevention of abrupt closure and restenosis after PTCA. Clinical studies evaluating the use of heparin delivery via the infusion sleeve are under way.14
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
| Footnotes |
|---|
This work was supported in part by LocalMed, Inc, Palo Alto, Calif. Some of the authors are employees (A.V.K., J.R.K., G.W.G., E.J.K.) or board members (A.V.K., J.B.S.) of LocalMed, Inc, the manufacturer of the drug-delivery device discussed in the article.
| References |
|---|
|
|
|---|
2.
The Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO) IIa Investigators. Randomized
trial of intravenous heparin versus recombinant hirudin for
acute coronary syndromes.
Circulation. 1994;90:1631-1637.
3.
Antman EM, for the TIMI 9A Investigators.
Hirudin in acute myocardial infarction: safety report from the
Thrombolysis and Thrombin Inhibition in Myocardial
Infarction (TIMI) 9A trial. Circulation. 1994;90:1624-1630.
4. Wolinsky H, Thung SN. Use of a perforated balloon catheter to deliver concentrated heparin into the wall of the normal canine artery. J Am Coll Cardiol. 1990;15:475-480. [Abstract]
5. Santoian EC, Gravanis MB, Anderberg K, Scott NA, Karas SP, Schneider JE, King SBJ III. Use of a porous infusion balloon in swine coronary arteries: low pressure minimizes arterial damage. Circulation. 1991;84:591. Abstract.
6. Lincoff AM, Furst JG, Penn MS, Lee P, MacIsaac AI, Chisolm GM, Topol EJ, Ellis SG. Efficiency of solute transfer by a microporous balloon catheter in the porcine coronary model of arterial injury. J Am Coll Cardiol. 1994;23:18A. Abstract.
7. Stadius ML, Collins C, Kernoff R. Local infusion balloon angioplasty to obviate restenosis compared with conventional balloon angioplasty in an experimental model of atherosclerosis. Am Heart J. 1993;126:47-56. [Medline] [Order article via Infotrieve]
8.
Lam JYT, Chesebro JM, Steele PM, Badimon L, Fuster V.
Is vasospasm related to platelet deposition? Relationship in
a porcine preparation of arterial injury in vivo.
Circulation. 1987;75:243-248.
9.
Lam JYT, Badimon JJ, Ellefson RD, Fuster V, Chesebro
JH. Cod liver oil alters platelet-arterial
wall response to injury in pigs. Circ Res. 1992;71:769-775.
10. Fram DB, Aretz TA, Azrin MA, Mitchel JF, Samady H, Gillam LD, Sahatjian R, Waters D, McKay RG. Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. J Am Coll Cardiol. 1994;23:1570-1577. [Abstract]
11.
Kaplan AV, Leung LLK, Leung W-H, Grant GW, McDougall
IR, Fischell TA. Roles of thrombin and platelet membrane
glycoprotein IIb/IIIa in
platelet-subendothelial deposition after
angioplasty in an ex vivo whole artery model.
Circulation. 1991;84:1279-1288.
12.
The EPIC Investigators. Use of a monoclonal
antibody directed against the platelet glycoprotein
IIb/IIIa receptor in high-risk coronary
angioplasty. N Engl J Med. 1994;330:956-961.
13. Riessen R, Isner JM. Prospects for site-specific delivery of pharmacologic and molecular therapies. J Am Coll Cardiol. 1994;23:1234-1244. [Abstract]
14. Kaplan AV, Vandormael M, Bartorelli A, Hofmann M, Stoerger H, Simpson JB, Reifart N. Heparin delivery at the site of angioplasty with a novel drug delivery sleeve: initial clinical series. J Am Coll Cardiol. 1995;25:286A. Abstract.
This article has been cited by other articles:
![]() |
X. Yang Imaging of Vascular Gene Therapy Radiology, July 1, 2003; 228(1): 36 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Chandrasekar and J.-F. Tanguay Local delivery of 17-beta-estradiol decreases neointimal hyperplasia after coronary angioplasty in a porcine model J. Am. Coll. Cardiol., November 15, 2000; 36(6): 1972 - 1978. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1995 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |